Shopping Cart
Remove All
Your shopping cart is currently empty
CGP 78608 hydrochloride is a specific antagonist at the glycine binding site of the NMDA receptor (IC50 = 6 nM). CGP 78608 hydrochloride exhibits anticonvulsant activity. CGP 78608 hydrochloride potentiates GluN1/GluN3A-mediated glycine currents (estimated EC50 = 26.3 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $87 | In Stock | In Stock | |
| 5 mg | $197 | In Stock | In Stock | |
| 10 mg | $243 | In Stock | - | |
| 25 mg | $535 | In Stock | - | |
| 50 mg | $773 | 8-10weeks | 8-10weeks | |
| 100 mg | $1,080 | 8-10weeks | 8-10weeks |
| Description | CGP 78608 hydrochloride is a specific antagonist at the glycine binding site of the NMDA receptor (IC50 = 6 nM). CGP 78608 hydrochloride exhibits anticonvulsant activity. CGP 78608 hydrochloride potentiates GluN1/GluN3A-mediated glycine currents (estimated EC50 = 26.3 nM). |
| Targets&IC50 | NMDAR:6 nM |
| In vitro | CGP 78608 hydrochloride reduces ammonia-dependent cGMP synthesis and relieves ammonia neurotoxicity[2]. CGP-78608 hydrochloride reduces glycine sensitivity of GluN1 and GluN3A receptors[3]. |
| In vivo | CGP-78608 (i.p.) exhibits anticonvulsant effects in the electroshock-induced convulsions assay in mice[1]. |
| Synonyms | PAMQX |
| Molecular Weight | 414.58 |
| Formula | C11H14BrClN3O5P |
| Cas No. | 1135278-54-4 |
| Smiles | C(N[C@@H](P(=O)(O)O)C)C1=C2C(NC(=O)C(=O)N2)=CC(Br)=C1.Cl |
| Relative Density. | 1.31g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 37.4 mg/mL (90.21 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.